Multifunctional TK-VLPs nanocarrier for tumor-targeted delivery

Ren, Yachao; Mu, Yu; Jiang, Lei; Yu, Hui; Yang, Shuman; Wang, Jianzhong; Zhang, Hua; Sun, Haiyan; Cui-hong, Xiao; Peng, Haisheng; Zhou, Yulong; Lu, Weiyue

doi:10.1016/j.ijpharm.2016.02.037

Cited by 7 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43, 44 We are also currently investigating complement activation prompted by engineered virus-like particles, which are of a more therapeutically-viable scale (∼ 30 nm in diameter). At this size, the EPR effect can be exploited 45 and the particles can be carried by lymphatic conduits. 46 …”

Section: Resultsmentioning

confidence: 99%

Fc microparticles can modulate the physical extent and magnitude of complement activity

et al. 2017

View full text Add to dashboard Cite

The complement system is an integral component of the humoral immune system, and describes a cascade of interacting proteins responsible for the opsonization and lysis of foreign pathogens, in addition to the recruitment of immune cells. However, complement activation is also implicated in the progression and complication of immune dysfunctions such as sepsis. Microparticle (MP) biomaterials capable of tuning the local magnitude of serum complement activation could improve complement-mediated cytotoxicity to serum-resistant bacteria or calm an overactive immune response during sepsis. We demonstrate that model Fc-functionalized microparticles can be designed to either enhance or diminish the local cytotoxic effect of complement activation in human serum. The particles were formed with either the antibody Fc domains oriented outward from the particle surface or randomly adsorbed in a non-oriented fashion. In the oriented Fc form, complement products were directly sequestered to the particle surface, including C5a, a potent anaphylatoxin that, when elevated, is associated with poor sepsis prognosis. The oriented particle also lowered the cytotoxicity of serum and thus decreased the antibiotic effect when compared to serum alone. Conversely, the non-oriented microparticles were found to sequester similar levels of C5a, but much lower levels of iC3b and TCC on the microparticle surface, thereby increasing the amount of the soluble terminal complement complex. In addition, the non-oriented microparticles extend the distance over which TCC forms and enhance serum cytotoxicity to bacteria. Together, these two types of complement-modulating particles provide the first biomaterial that can functionally modify the range of complement activation at sites distant from the particle surface. Thus, biomaterials that exploit Fc presentation provide new possibilities to functionally modulate complement activation to achieve a desired clinical result.

show abstract

Section: Resultsmentioning

confidence: 99%

Fc microparticles can modulate the physical extent and magnitude of complement activity

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A targeting function may be added to VLPs by genetic engineering. Insertions or extensions of peptides and proteins may be directly inserted into the main amino acid sequences of the coat proteins (CPs), allowing their presentation on either the interior or outer surface of the VLP [195][196][197].…”

Section: 5mentioning

confidence: 99%

Nanomaterials: A Promising Therapeutic Approach for Cardiovascular Diseases

Chopra

Bibi

Mishra

et al. 2022

Journal of Nanomaterials

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are a primary cause of death globally. A few classic and hybrid treatments exist to treat CVDs. However, they lack in both safety and effectiveness. Thus, innovative nanomaterials for disease diagnosis and treatment are urgently required. The tiny size of nanomaterials allows them to reach more areas of the heart and arteries, making them ideal for CVDs. Atherosclerosis causes arterial stenosis and reduced blood flow. The most common treatment is medication and surgery to stabilize the disease. Nanotechnologies are crucial in treating vascular disease. Nanomaterials may be able to deliver medications to lesion sites after being infused into the circulation. Newer point-of-care devices have also been considered together with nanomaterials. For example, this study will look at the use of nanomaterials in imaging, diagnosing, and treating CVDs.

show abstract

“…Cell targeting delivery of drugs could also be achieved by insertion of polypeptides into the surface loop of capsid proteins. For instance, porcine parvovirus capsid protein VP2 (PPV VP2) can self-assemble to VLP, and a 12-residue peptide (TWYKIAFQRNRK), termed as the TK peptide, was inserted into the loop region of VP2, and this VLP could specifically target and deliver drugs towards Caco-2 cells and HUVEC cells by binding to the integrin α6β1 receptor and integrin αvβ3 receptor, respectively [53]. Similarly, MS2-and Qβ-VLP were modified with a targeting peptide, SP49 (SFSIIHTPILPL), on its surface for delivery of chemotherapeutic drugs.…”

Section: Vlps For Compound Deliverymentioning

confidence: 99%

Virus-like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds

Lin

et al. 2022

Viruses

View full text Add to dashboard Cite

Virus-like particles (VLPs) are nanostructures assemble from viral proteins. Besides widely used for vaccine development, VLPs have also been explored as nanocarriers for cargo delivery as they combine the key advantages of viral and non-viral vectors. While it protects cargo molecules from degradation, the VLP has good cell penetrating property to mediate cargo passing the cell membrane and released into cells, making the VLP an ideal tool for intracellular delivery of biomolecules and drugs. Great progresses have been achieved and multiple challenges are still on the way for broad applications of VLP as delivery vectors. Here we summarize current advances and applications in VLP as a delivery vector. Progresses on delivery of different types of biomolecules as well as drugs by VLPs are introduced, and the strategies for cargo packaging are highlighted which is one of the key steps for VLP mediated intracellular delivery. Production and applications of VLPs are also briefly reviewed, with a discussion on future challenges in this rapidly developing field.

show abstract

Multifunctional TK-VLPs nanocarrier for tumor-targeted delivery

Cited by 7 publications

References 42 publications

Fc microparticles can modulate the physical extent and magnitude of complement activity

Fc microparticles can modulate the physical extent and magnitude of complement activity

Nanomaterials: A Promising Therapeutic Approach for Cardiovascular Diseases

Virus-like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds

Contact Info

Product

Resources

About